Last updated at 04 Jul 2024 02:43 AM
Director
DIN: 02177137
Rakesh Jain is currently associated with 3 companies as Director. They serve as a Director at KAVERI SAREES PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 02177137.Rakesh Jain has previously been associated with 3 companies in roles such as Additional Director and Director.Rakesh Jain is currently involved in 1 different role. Their most recent position is with METACINE PHARMACEUTICALS PRIVATE LIMITED as a Director. The first company Rakesh Jain was appointed to as a director was KAVERI SAREES PRIVATE LIMITED. Rakesh Jain is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Rakesh Jain is currently associated with 3 companies as Director. They serve as a Director at KAVERI SAREES PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 02177137.Rakesh Jain has previously been associated with 3 companies in roles such as Additional Director and Director.Rakesh Jain is currently involved in 1 different role. Their most recent position is with METACINE PHARMACEUTICALS PRIVATE LIMITED as a Director. The first company Rakesh Jain was appointed to as a director was KAVERI SAREES PRIVATE LIMITED. Rakesh Jain is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
3
Male
India
Gain instant access to verified contact details.
Current Companies (3)
Current LLPs (0)
Past Companies (3)
5 Years 2y 6m Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| KAVERI SAREES PRIVATE LIMITED | Director | 29-Sep-2017 |
| POONAM INVESTMENTS AND FINANCIAL CONSULTANTS LIMITED | Director | 29-Sep-2018 |
| METACINE PHARMACEUTICALS PRIVATE LIMITED | Director | 06-Mar-2023 |